Affiliated Hospital of Weifang Medical University, School of Clinical Medicine, Weifang Medical University, Weifang, China.
Department of Hematology, Linyi People's Hospital, Shandong University, Linyi, 276000, Shandong, China.
Ann Hematol. 2024 May;103(5):1435-1454. doi: 10.1007/s00277-023-05395-z. Epub 2023 Aug 15.
Lymphomas, complex and heterogeneous malignant tumors, originate from the lymphopoietic system. These tumors are notorious for their high recurrence rates and resistance to treatment, which leads to poor prognoses. As ongoing research has shown, epigenetic modifications like DNA methylation, histone modifications, non-coding RNA regulation, and RNA modifications play crucial roles in lymphoma pathogenesis. Epigenetic modification-targeting drugs have exhibited therapeutic efficacy and tolerability in both monotherapy and combination lymphoma therapy. This review discusses pathogenic mechanisms and potential epigenetic therapeutic targets in common lymphomas, offering new avenues for lymphoma diagnosis and treatment. We also discuss the shortcomings of current lymphoma treatments, while suggesting potential areas for future research, in order to improve the prediction and prognosis of lymphoma.
淋巴瘤是一种复杂且异质性的恶性肿瘤，起源于淋巴造血系统。这些肿瘤以高复发率和治疗耐药性而闻名，导致预后不良。正如正在进行的研究表明，表观遗传修饰如 DNA 甲基化、组蛋白修饰、非编码 RNA 调控和 RNA 修饰在淋巴瘤发病机制中发挥着关键作用。表观遗传修饰靶向药物在单药治疗和联合淋巴瘤治疗中均显示出治疗效果和耐受性。本综述讨论了常见淋巴瘤中的发病机制和潜在的表观遗传治疗靶点，为淋巴瘤的诊断和治疗提供了新的途径。我们还讨论了当前淋巴瘤治疗的不足之处，同时提出了未来研究的潜在方向，以改善淋巴瘤的预测和预后。
